Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/002—Protozoa antigens
  • A61K39/012—Coccidia antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
  • A61K2039/541—Mucosal route
  • A61K2039/542—Mucosal route oral/gastrointestinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
  • A61K2039/552—Veterinary vaccine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55583—Polysaccharides

Definitions

• the present invention relates to the fields of veterinary parasitology and—vaccinology; more specifically the invention relates to a Coccidiosis vaccine for poultry comprising live Eimeria oocysts; to methods for the preparation of the Coccidiosis vaccine; to a kit of parts; and to methods of administration of the Coccidiosis vaccine.
• Eimeria are protozoan parasites of the phylum Apicomplexa, and the class Coccidia, and occur worldwide. When infecting poultry, they cause a medium to severe enteric disease-complex, called: Coccidiosis. Eimeria have a complex lifecycle with multiple stages, some developing outside the host. Eimeria infection occurs by ingestion of sporulated oocysts and can happen from the first day of age. In the gut sporozoites are released which then colonize a section of the bird's intestine, by invading gut epithelial cells. Replication leads to release of merozoite stages, and rupture of gut-epithelial cells from the host.
• Eimeria that infect poultry can be identified in a number of ways, routinely by microscopic size and appearance of the coccidia. Also, the different Eimeria species tend to colonise different areas of the avian intestines.
• Symptoms of Eimeria infection in poultry vary from loss of appetite to bloody diarrhoea and organ failure due to build-up of necrotic tissue in the intestines. Consequences are a drop in feed conversion rate, reduced growth rate, reduced egg production, and susceptibility to secondary infections, all causing major discomfort to affected birds, and serious economic damage to a commercial poultry operation.
• Eimeria infection and subsequent disease in poultry is preferably combated by vaccination.
• live vaccines comprising sporulated oocysts from one or more species of Eimeria .
• Their natural replication in the bird induces a strong immunity, by both humoral and cellular routes of the immune system.
• the live coccidia can be of wild type or of attenuated pathotype.
• a special class of attenuated Eimeria are the so-called precocious strains, which are Eimeria that will complete their lifecycle in a bird in fewer than normal number of cycles. These produce lower numbers of oocyst output and also less damage to a target's intestine.
• precocious strains which are Eimeria that will complete their lifecycle in a bird in fewer than normal number of cycles.
• Eimeria vaccine efficacy is usually determined by comparing the main criteria for infection and disease: gut lesion score, reduction of oocyst output, and effect on weight gain, after a challenge infection with a virulent Eimeria strain.
• gut lesion score a criteria for infection and disease
• reduction of oocyst output a criteria for assessing Eimeria vaccine efficacy
• a paper describing the relevance of these criteria for assessing Eimeria vaccine efficacy is: Williams & Catchpole, (2000, Vaccine, vol. 18, p. 1178-1185).
• a live Eimeria vaccine will contain sporulated coccidia from several Eimeria species, as immunity is species specific.
• Coccidiosis vaccines for poultry are: from MSD Animal Health, the vaccine lines: CoccivacTM, ParacoxTM, or FortegraTM which contain live sporulated coccidia from different strains of up to 8 species of Eimeria .
• Other commercial Eimeria vaccines are ImmucoxTM (Ceva), and InovocoxTM (Zoetis).
• Such vaccines are commonly administered by some method of mass vaccination in order to reduce costs, such as by spray to the body or the feed, or via the drinking water. Because field infection pressure exists from the first day of age, therefore vaccination is preferably applied as young as possible. This can conveniently be done by spray administration at the hatchery, when chicks have just hatched and are kept in open trays. This route reaches the body of the birds as well as their direct surroundings. The vaccine is then ingested by the birds via oral-, nasal, or ocular route by their tendency to peck-up droplets and to preen their feathers.
• spray vaccines are commonly provided with a bright colour such as green (chlorophyll) or red (carmine).
• the bright colour enhances visibility and appeals to the birds' curiosity, which stimulates pecking and preening.
• Eimeria spray vaccines are relatively large and heavy micro-organisms (15-30 ⁇ m diameter oval shapes), and therefore have a tendency to settle in liquid carriers under influence of gravity. This is especially disadvantageous when the vaccine applied uses Eimeria of different species, which may have different sized coccidia; the heaver species then tend to settle more quickly and may not be ingested to the full amount required.
• existing vaccines may contain a rheology modifier as a suspending aid.
• the ParacoxTM 8 vaccine contains 0.3% w/v Xanthan gum per animal dose. This keeps the different coccidia suspended and mixed evenly during administration. However, the viscosity of this vaccine is low.
• Xanthan gum is a high molecular weight polysaccharide that is produced by bacteria of the Xanthomonas genus. These days it is produced by the industrial fermentation of X. campestris on for instance whey. Xanthan gum is used in a variety of products, such as pharmaceuticals and foods, as a stabiliser of emulsions, or as a thickener to influence a product's viscosity. Xanthan gum is a pseudoplastic, i.e. it has shear-thinning properties. It is available from different commercial suppliers, e.g. as KeltrolTM from CP Kelco. Details and properties of Xanthan gum are described for example in the ‘Xanthan book’, 8 th ed., 2008, cpkelco.com.
• WO 2005/099.617 describes a coccidial Eimeria vaccine that is provided as a soft gel containing about 1% carrageenan, which is a seaweed-derived polysaccharide, commonly used in the food industry for its gelling properties.
• carrageenan which is a seaweed-derived polysaccharide, commonly used in the food industry for its gelling properties.
• a special delivery system is required, a ‘gel dispenser’ with a special manifold that produces a stream of gel-droplets.
• the new Coccidiosis vaccine is quickly and comprehensively ingested by the birds, resulting in an improved vaccine take (level of replication of vaccine coccidia in the gut). This, because the time from ingestion to initiation of the first round of replication was significantly reduced.
• the new vaccine can be delivered with a conventional spray apparatus such as a standard hatchery spray cabinet or a back-pack sprayer. Also, the vaccine composition does not need constant stirring during the spray administration.
• the droplets formed from the new vaccine do not wet the chicks upon spray vaccination, preventing the negative side-effects of chilling, especially for day-old chicks.
• this vaccine composition has a viscosity that—upon application as a spray—allows the formation of beads of a size that is attractive to the birds for pecking up, whereby the vaccine's ingestion is more rapid and comprehensive than for the less viscous Eimeria spray vaccines of the prior art.
• the coccidia displayed a reduced time for gut-transit and establishment of an infection, possibly as an effect of the encapsulation by the Xanthan gum polysaccharide, which helps the ingested coccidia to more readily establish themselves in the birds intestines, and so lead to an earlier development of immunity.
• a Coccidiosis vaccine of this composition has a relatively high viscosity of between about 200 and about 4000 mPa ⁇ s, which upon administration as a coarse spray, was found to be ideally suited to produce beads of a size between about 1 and about 4 mm in diameter. Beads of this size (especially when highly visible from a colorant) appeared to be very appealing to the birds and were quickly and effectively ingested.
• Xanthan gum concentrations did not provide correct bead formation upon spray: at concentrations of Xanthan gum higher than about 1.5% w/v, no separated beads were produced, and at concentrations of Xanthan gum lower than about 0.3% w/v, the spray was too wet, not giving good beads and causing wetting and chilling of the birds.
• the invention relates to a Coccidiosis vaccine for poultry, comprising live oocysts of at least one species of Eimeria in a pharmaceutically acceptable carrier, characterised in that the vaccine comprises 0.3-1.5% w/v Xanthan gum which gives the vaccine a viscosity between 200 and 4000 mPa ⁇ s.
• Chronicoccidiosis is well known as an intestinal disease-complex caused by coccidial parasites, such as Eimeria.
• a “vaccine” is well known to be a composition that has an inherent medical effect.
• a vaccine comprises an immunologically active component, and a pharmaceutically acceptable carrier.
• the ‘immunologically active component’ is one or more antigenic molecule(s), here: live Eimeria coccidia, that are recognised by the immune system of a target, and induces a protective immunological response.
• the response may originate from the targets' innate- and/or from the acquired immune system, and may be of the cellular—and/or of the humoral type.
• a vaccine generally is efficacious in reducing the level or the extent of an infection, for example by reducing the parasitic load or shortening the duration of the parasite's replication in a host animal.
• a vaccine generally is effective in reducing or ameliorating the (clinical) symptoms of disease that may be caused by such infection or replication, or by the animal's response to that infection or replication.
• the effect of a Coccidiosis vaccine according to the invention is the prevention or reduction in poultry of an infection by an Eimeria and/or of one or more signs of Coccidial disease that are associated with such infection or replication.
• Such (clinical) signs are: intestinal lesions, bodyweight gain, and oocyst output.
• Such a Coccidiosis vaccine may colloquially also be referred to as a vaccine ‘against’ Eimeria or against Coccidiosis, or as an ‘ Eimeria vaccine’.
• Pigtry refers to avians of agricultural relevance, such as: chicken, turkey, duck, goose, partridge, peacock, quail, pigeon, pheasant, guinea fowl, or ostrich.
• any such text section, paragraph, claim, etc. can therefore also relate to one or more embodiment(s) wherein the term “comprising” (or its variants) is replaced by terms such as “consist of”, “consisting of”, or “consist essentially of”.
• oocysts are well known micro-organisms that are one of the life-cycle stages of an Apicomplexan parasite such as an Eimeria.
• the oocysts are “live” when they are capable of initiating an Eimeria replicative cycle under the appropriate conditions, such as in the intestines of a bird.
• An “ Eimeria ” is well known in the art as a parasite belonging to the Eimeriidae family. These parasites and their induced diseases are described in well-known handbooks (supra).
• An Eimeria displays the characterising features of its taxonomic group-members such as the morphologic, genomic, and biochemical characteristics, as well as the biological characteristics such as physiologic, immunologic, or pathologic behaviour.
• the classification of a micro-organism as a particular “species” is based on a combination of such features.
• the invention therefore also includes Eimeria that are sub-classified therefrom in any way, for instance as a subspecies, strain, isolate, genotype, variant, subtype or subgroup and the like.
• the Eimeria for the invention can replicate in a species of poultry, and for example comprise, but are not limited to, the Eimeria species: E. acervulina, E. tenella, E. maxima, E. brunetti, E. mitis, E. mivati, E. necatrix, E. praecox, E. hagani, E. meleagrimitis (type 1 and type 2), E. adenoides, E. gallopavonis, E. dispersa, E. innocua, E. subrotunda , and E. meleagridis.
• E. acervulina E. tenella, E. maxima, E. brunetti, E. mitis, E. mivati, E. necatrix, E. praecox, E. hagani, E. meleagrimitis (type 1 and type 2)
• E. adenoides E. gallopavonis, E. dispersa, E. innocua, E. subrotund
• Eimeria parasites for use in the invention can be obtained from a variety of sources, e.g. as original field isolates from a poultry house, or as reference- or laboratory strain from various laboratories and (depository) institutions.
• the “at least one species” refers to the practice to include Eimeria of more than one species in a coccidial Eimeria vaccine, to provide broad immune protection.
• the vaccine can comprise one or more strains of a particular species, to cover differences in prevalence.
• a “pharmaceutically acceptable carrier” for the invention is a liquid of a high grade of purity and sterile, for example water, a physiological salt solution, or a phosphate buffered saline solution.
• the carrier can e.g. be a buffer comprising further additives, such as stabilisers or preservatives.
• the concentration of salt that can be comprised in the final vaccine. This is for reasons of maintaining a palatable composition. Details are described in relation to the method for preparation and the sterilisation of Xanthan gum described below.
• Xanthan gum is the well-known polysaccharide that is generally available commercially, in several qualities and purities, for example as KeltrolTM, XanturalTM, or KelzanTM, from CP Kelco.
• the concentration of the Xanthan gum is determined as “% w/v”, i.e. a percentage in weight-per-volume. This is to be determined on the basis of the final vaccine composition as it is in an animal dose ready for administration to the birds.
• the vaccine according to the invention or parts thereof may be produced, marketed, or stored in a more concentrated form, e.g. concentrated 2 or more times, which is then diluted to the final use concentration shortly before administration.
• This may be advantageous for stability, or for logistic reasons, to reduce volume and save costs for packaging and transportation.
• the resulting vaccine composition acquires a relatively high viscosity of between 200 and 4000 mPa ⁇ s, respectively.
• Viscosity can be measured using a variety of suitable equipment; for the invention, preferred method of viscosity measurement is by using the rotating spindle technique, whereby the samples are measured when equilibrated at a constant temperature, e.g. 25° C. Details are described in the Examples section.
• the vaccine composition does not contain any other rheology modifier such as a polysaccharide, gum, gelling agent, or thickener that can substantially raise the viscosity of an aqueous vaccine composition, besides Xanthan gum.
• any other rheology modifier such as a polysaccharide, gum, gelling agent, or thickener that can substantially raise the viscosity of an aqueous vaccine composition, besides Xanthan gum.
• the Xanthan gum is the only rheology modifier in the vaccine composition.
• the Coccidiosis vaccine according to the invention comprises 0.4-1.2% w/v Xanthan gum.
• the vaccine comprises 0.5-1% w/v Xanthan gum, 0.5-0.9% w/v, 0.5-0.8% w/v, or even 0.5-0.7% w/v Xanthan gum, in that order of preference.
• the Coccidiosis vaccine according to the invention comprises about 0.6% w/v Xanthan gum.
• “about” indicates that a number can vary between ⁇ 25% around its indicated value.
• “about” means ⁇ 20% around its value, more preferably “about” means ⁇ 15, 12, 10, 8, 6, 5, 4, 3, 2% around its value, or even “about” means ⁇ 1% around its value, in that order of preference.
• the target poultry for the Coccidiosis vaccine according to the invention is selected from the group consisting of chicken, turkey, duck, and geese.
• the poultry is chicken or turkey, because for these poultry species the economic impact on the poultry sector of Eimeria infection is the largest. Most preferred is chicken.
• the target birds may be of any type such as layers, breeders, broilers, combination breeds, or parental lines of any of such breeds. Preferred type is broilers.
• the vaccine according to the invention can in principle comprise any Eimeria coccidia that is capable of infecting or replicating in a poultry.
• the live Eimeria coccidia are from an attenuated strain of Eimeria.
• Attenuated Eimeria can be obtained by selection of naturally occurring Eimeria differing in pathogenicity. Alternatively attenuated Eimeria can be obtained by in vitro passageing and selection, or via recombinant DNA technology, all well known in the art.
• the attenuated Eimeria are precocious.
• the Coccidiosis vaccine according to the invention comprises the same coccidia species as present in an existing commercial live coccidia based Eimeria vaccine; more preferred: the same coccidia as in the group consisting of the vaccine lines: Coccivac, Paracox, and Fortegra.
• the at least one species of Eimeria is one or more or all, selected from the group consisting of: E. acervulina, E. tenella, E. maxima, E. brunetti, E. mitis, E. praecox, E. mivati, E. hagani , and E. necatrix.
• the at least one species of Eimeria is one or more or all, selected from the group consisting of: E. adenoeides, E. meleagrimitis type 1 , E. meleagrimitis type 2 , E. gallopavonis , and E. dispersa.
• the exact amount of Eimeria coccidia per dose of the vaccine according to the invention is not so critical, because the coccidia will readily replicate and colonise the hosts intestine.
• the vaccine dose only needs to be sufficient to initiate such a productive infection.
• a higher inoculum dose hardly shortens the time it takes to reach the optimal colonisation in the host; and very high doses are not attractive for economic reasons.
• too high doses of vaccine coccidia may cause some pathology by themselves.
• too low a dose although perhaps capable of establishing an Eimeria infection, may take too much time for a proper onset of immunity.
• a preferred inoculum dose is therefore between about 1 ⁇ 10 ⁇ 1 and about 1 ⁇ 10 ⁇ 5 sporulated oocysts of a species of Eimeria per animal dose, more preferably between 1 ⁇ 10 ⁇ 2 and 1 ⁇ 10 ⁇ 4 oocysts per dose, between 100 and 5000, or even between 100 and 1000 oocysts/animal dose, in that order of preference.
• the optimal vaccine dose will depend e.g. on the target animal species, and on the species and the virulence of the Eimeria strain used, and may therefore be different for the various Eimeria species in one combination vaccine.
• the volume per animal dose of the Coccidiosis vaccine according to the invention can be optimised according to the intended route of application, e.g. for a body spray vaccination the dose may be between about 10 ⁇ l and 1 ml per bird.
• the volume of spray vaccine per bird is between 0.1 and 0.5 ml per bird, more preferably between 0.2 and 0.3 ml per bird.
• the vaccine can be administered by spray onto the feed, or as a liquid to the drinking water.
• Finding the optimal volume and dose for the various routes of administration, by determining what is an immunologically effective amount of Eimeria coccidia per animal dose of vaccine according to the invention, is well within the routine capabilities of the skilled artisan.
• Determining the effectiveness of a Coccidiosis vaccine according to the invention can e.g. be done by monitoring the immunological response following vaccination or after a challenge infection, e.g. by monitoring the targets' signs of disease, clinical scores, serological parameters, or by re-isolation of the pathogen, and comparing these results to a vaccination-challenge response seen in mock vaccinated animals.
• the age, weight, sex, immunological status, and other parameters of the target poultry for the Coccidiosis vaccine according to the invention are not critical although it is evidently favourable to vaccinate healthy targets, and to vaccinate as early as possible to prevent (the consequences of) an early infection by a pathogenic Eimeria.
• the Coccidiosis vaccine according to the invention is preferably administered at the day of hatch (i.e. at 1 day old).
• a combination vaccine comprises in addition to the Coccidiosis vaccine according to the invention, another immunologically active compound.
• this can be any live or killed micro-organism or subunit product, provided this does not reduce the stability or the replicative capacity of the Eimeria coccidia.
• the additional immunoactive component(s) must be compatible with the intended oral route of applicating the Coccidiosis vaccine.
• the additional immunologically active compound may be an antigen, an immune enhancing substance, a cytokine, and/or a vaccine
• the Coccidiosis vaccine according to the invention may itself be added to a vaccine.
• the vaccine according to the invention is characterised in that the vaccine comprises one or more additional immunoactive component(s).
• the vaccine according to the invention is a combination vaccine, comprising at least one additional antigen derived from a micro-organism that is pathogenic to poultry.
• the additional antigen may be a live, live attenuated, or killed micro-organism, or a part—or subunit antigen thereof.
• the additional antigen from a micro-organism that is pathogenic to poultry is one or more, selected from the groups consisting of:
• Most preferred additional antigen is selected from: IBV, NDV, IBDV, ILTV, TRT, AIV, MDV, Mycoplasma , and Salmonella.
• the additional immunoactive component is an adjuvant.
• adjuvant is a well-known vaccine ingredient, which in general is a substance that stimulates the immune response of a target bird in a non-specific manner. Many different adjuvants are known in the art.
• the adjuvant should be mild enough not to affect the stability or replicative potential of the live Eimeria coccidia.
• the adjuvant is a cytokine.
• a Coccidiosis vaccine according to the invention can advantageously be combined with a pharmaceutical component such as an antibiotic, a hormone, and/or an anti-inflammatory drug.
• an anti-coccidial compound is also possible, provided that the Eimeria coccidia in the vaccine are not sensitive to that particular drug.
• the Coccidiosis vaccine according to the invention may contain one or more components that aid the viability and quality of the live Eimeria coccidia for use in the invention, thereby promoting the productive replication and establishment of a colonisation in the intestines of target poultry.
• the additive may be a stabiliser, to stabilise the quantity and the quality of an Eimeria coccidia for the invention during storage, handling, administration or ingestion.
• stabilisers are large molecules of high molecular weight, such as lipids, carbohydrates, or proteins; for instance milk-powder, gelatine, serum albumin, sorbitol, trehalose, spermidine, dextrane or polyvinyl pyrrolidone.
• preservatives such as thimerosal, merthiolate, phenolic compounds, or gentamicin.
• a Coccidiosis vaccine according to the invention can be used either as a prophylactic- or as a therapeutic treatment, or both, as it interferes both with the establishment and with the progression of an infection by an Eimeria.
• the vaccine composition may contain a certain concentration of a metal salt.
• this can be required to stabilise the Xanthan gum when it needs to be sterilised by heating.
• the salt concentration should not exceed a level of 0.4% w/v in the final vaccine composition.
• the vaccine comprises less than about 0.4% w/v metal salt.
• one or more or all of the conditions apply selected from the group consisting of:
• the Coccidiosis vaccine according to the invention can be prepared from live Eimeria coccidia by methods well known and readily applicable by a person skilled in the art.
• Eimeria parasites are produced industrially in donor poultry animals, and isolated from their faeces by well-known techniques such as centrifugation and salt flotation, followed by sporulation and sterilisation, and finally counting by light microscopy.
• Sporulation can be performed e.g. using potassium-dichromate, and sterilisation can be done using sodium-hypochlorite or beta-propiolactone.
• the sporulated Eimeria oocysts are then formulated with a pharmaceutical carrier into a vaccine and the final product is apportioned into appropriate sized containers and packaged.
• the invention relates to a method for the preparation of a Coccidiosis vaccine according to the invention, characterised in that the method comprises the step of admixing live oocysts of at least one species of Eimeria in a pharmaceutically acceptable carrier, with Xanthan gum up to 0.3-1.5% w/v.
• the Xanthan gum may be admixed with the coccidia as a powder.
• the Xanthan gum is admixed as a solution. That allows for a composition with Xanthan gum to be prepared separately from a composition comprising the Eimeria coccidia. Similarly, a composition comprising the coccidia may be prepared and stored separately in a concentrated form, to be mixed with the Xanthan gum shortly before use. This provides flexibility in production planning and logistics, and can assist in maintaining the stability of the coccidia.
• composition comprising Xanthan gum then serves as a diluent for a concentrated composition of coccidia.
• a dilution occurs of both these compositions. Consequently, to arrive at a specific final concentration of coccidia and Xanthan gum in the resulting Coccidiosis vaccine according to the invention, the compositions being mixed need to be of higher than final strength to allow for this dilution.
• compositions comprising the Xanthan gum when the two types of compositions are mixed at equal volumes, both need to be at double the desired final concentration of their components; e.g. the composition comprising the Xanthan gum in this case would need to comprise between 0.6 and 3.0% w/v Xanthan gum.
• the method for the preparation of a Coccidiosis vaccine according to the invention is characterised in that the Xanthan gum is provided in a composition of which the concentration is such that after the admixing the resulting vaccine comprises 0.3-1.5% w/v Xanthan gum.
• this allows the vaccine according to the invention to be supplied as a kit of parts for preparing the Coccidiosis vaccine according to the invention, wherein the kit comprises separate containers, one with live coccidia, and one with Xanthan gum that is to be used as a diluent for the coccidia, and whereby the containers combined can be used to prepare the vaccine according to the invention.
• the invention relates to a kit of parts for preparing a Coccidiosis vaccine according to the invention, characterised in that the kit comprises at least two containers: one container comprising a composition comprising live oocysts of at least one species of Eimeria in a pharmaceutically acceptable carrier, and one container comprising a composition comprising Xanthan gum, whereby the concentration of the composition comprising Xanthan gum is such that after combining the compositions of both containers, the resulting vaccine comprises 0.3-1.5% w/v Xanthan gum.
• the kit of parts according to the invention comprises instructions for the use of said kit and/or the preparation of the Coccidiosis vaccine according to the invention.
• the instructions for use comprised with the kit of parts according to the invention, may for example be provided by way of information written on, or attached to, one or all of the container(s), or on a box containing one or all of the container(s). Also the instructions may be present on a leaflet packaged with one or all of the container(s), such as a patient information leaflet or a package insert. Also, the instructions for use may be provided by way of a reference to instructions in electronic form, such as information viewable on, or downloadable from, an internet website from the distributor of the kit, and the like.
• kit of parts according to the invention may also be an offer of the mentioned parts (relating to commercial sale), for example on an internet website, for combined use in a method for preparation of the Coccidiosis vaccine according to the invention.
• kits of parts allow for the separate sterilisation of the composition comprising Xanthan gum.
• the inventor found a way to allow the heat sterilisation of a composition comprising Xanthan gum without destroying its viscosity. Surprisingly it was found that this object can be met, and consequently one or more disadvantages of the prior art can be overcome, by providing a composition comprising Xanthan gum with a concentration of a metal salt of at least about 0.1% w/v; the % w/v in this case is to be calculated over the volume of the composition comprising the Xanthan gum and the metal salt.
• the metal salt was found to be able to effectively protect a composition comprising Xanthan gum during heat sterilisation against a severe (more than 15%) and irreversible loss of viscosity.
• the invention relates to a method for the heat sterilisation of a composition comprising Xanthan gum, characterised in that the method comprises admixing said composition with at least 0.1% w/v metal salt.
• a “heat sterilisation” involves an incubation for at least 15 minutes at at least 100° C.
• the metal salt in principle can be any metal salt, but preferably the metal salt is a salt from a mono- or bi-valent metal cation. More preferred the cation is an alkali-metal.
• the anion of the metal salt is preferably a halogen, sulphate, phosphate, nitrate, or acetate. More preferred a chloride.
• the metal salt is a halogen salt of an alkali-metal; even more preferably of sodium or potassium; even more preferably the metal salt is: a sodium-chloride, or a potassium-chloride.
• the method for the preparation of a Coccidiosis vaccine according to the invention is characterised in that the composition comprising Xanthan gum additionally contains a concentration of a metal salt of at least about 0.1% w/v.
• the concentration of the metal salt in the composition comprising Xanthan gum is such that the resulting vaccine comprises less than about 0.4% w/v metal salt.
• one or more or all of the conditions apply selected from the group consisting of:
• kit of parts according to the invention is characterised in that the composition comprising Xanthan gum additionally contains a concentration of a metal salt of at least about 0.1% w/v, and the concentration of the metal salt in said composition is such that the resulting vaccine comprises less than about 0.4% w/v metal salt.
• one or more or all of the conditions apply selected from the group consisting of:
• the vaccine composition may be further adapted.
• This is well within the capabilities of a skilled person, and generally involves the fine-tuning of the efficacy or the safety of the vaccine. This can be done by adapting the vaccine dose, quantity, frequency, or the route, by using the vaccine in another form or formulation, or by adapting the other constituents of the vaccine (e.g. stabilisers, carriers, adjuvants, diluents, and the like).
• a coccidial Eimeria vaccine may be mixed with a colouring agent.
• a Coccidiosis vaccine according to the invention may be prepared in freeze-dried form.
• Procedures for freeze-drying are known to persons skilled in the art, and equipment for freeze-drying at different scales is available commercially.
• the Eimeria parasite should be in a relatively robust form to survive the freezing, drying, storage, and thawing periods. Therefore a favourable embodiment is to freeze-dry the sporozoite form of the Eimeria for use in the invention.
• the vaccine is prepared in a freeze-dried form.
• the Coccidiosis vaccine according to the invention and methods for its preparation according to the invention, with all their advantageous implications, can also be described in alternate wording, focussing on the surprising and advantageous medical uses of the vaccine composition:
• the invention relates to a composition
• a composition comprising live oocysts of at least one species of Eimeria in a pharmaceutically acceptable carrier for use as a Coccidiosis vaccine for poultry, characterised in that the composition comprises 0.3-1.5% w/v Xanthan gum which gives said composition a viscosity between 200 and 4000 mPa ⁇ s.
• the invention relates to the use of a composition comprising live oocysts of at least one species of Eimeria in a pharmaceutically acceptable carrier for the manufacture of a Coccidiosis vaccine for poultry, characterised in that the composition comprises 0.3-1.5% w/v Xanthan gum which gives said composition a viscosity between 200 and 4000 mPa ⁇ s.
• the Coccidiosis vaccine according to the invention is preferably administered to the target birds in an optimal way in respect of its dose, volume, route, and formulation, as well in an optimal way with respect to the target's age, sex, or health status.
• the skilled person is perfectly capable of determining such optimal conditions for the vaccine administration.
• the Coccidiosis vaccine according to the invention is applied via a method of mass application, such as by spray, on the body or the feed, or via the drinking water. This reduces both the discomfort of vaccination to the target birds, as well as the labour costs.
• Suitable methods for the mass administration of Coccidiosis vaccine according to the invention should of course be compatible with a live Eimeria coccidium, and aim for reaching the intestines. Preferred methods are: by spray, or drinking water, or by (automated) injection into the egg, so-called in ovo vaccination. Suitable equipment for mass administration of a poultry vaccine is available commercially.
• the invention relates to a method of vaccination of poultry against Coccidiosis, characterised in that the method comprises administering the Coccidiosis vaccine according to the invention to said poultry as a body spray.
• the indication of the vaccine being a “body spray” does not require that all of the body of the birds is covered, it merely indicates that no particular part of the body needs to be specifically targeted. In addition, a significant part of the vaccine delivered in this way will not land on, or stay on, the body of the birds, but may end up on the floor. This is fine, as the birds will quickly start to peck at such droplets and ingest them.
• the advantageous properties of the Coccidiosis vaccine according to the invention when delivered to the body of the birds, are most prominent when applied as a coarse spray.
• vaccine beads form that are quickly ingested by the birds from the feathers or the floor.
• a method of vaccination of poultry according to the invention is characterised in that the spraying is applied as a coarse spray.
• a coarse spray applies droplet of a size over 50 ⁇ m in diameter.
• the droplets are preferably between 1 and 4 mm in size.
• Such a coarse spray can for example be applied using a hatchery sprayer when immunising day old chicks in hatching trays, or can be applied e.g. using a back-pack type sprayer when immunising older birds in a floor pen setting.
• the administration regime for applying the vaccine according to the invention to a target bird can be in single or in multiple doses, in a manner compatible with the formulation of the vaccine and with practical aspects of the animal husbandry.
• the regimen for a method of vaccination of poultry according to the invention is integrated into existing vaccination schedules of other vaccines that the target birds may require, in order to reduce stress to the animals and to reduce labour costs.
• These other vaccines can be administered in a simultaneous, concurrent, or sequential fashion, in a manner compatible with their registered use.
• the vaccine is administered in a combination with another poultry vaccine.
• the invention relates to a method for the prevention or reduction of an infection with Eimeria or of associated signs of disease in poultry, characterised in that the method comprises the administration to said poultry of a Coccidiosis vaccine according to the invention.
• the viscosity of a solution of Xanthan gum in water was determined under different conditions, testing the effect of heat sterilisation with or without the inclusion of a concentration of metal salt.
• Viscosity measurements were performed with a BrookfieldTM rotational viscometer according to the manufacturer's instructions. This equipment determines the viscosity of a liquid from the torque on a spindle, rotating at a defined number of rotations per minute, in a defined volume of that liquid. All samples were measured while equilibrated in a water bath at 25° C.
• the inventor tested a Xanthan gum vaccine formulation, next to a more traditional vaccine wherein the coccidia were diluted in water. It was tested if the vaccine would ‘bead’ on the birds, increasing the visibility of the vaccine, and leading to better vaccine ingestion and minimal wetting of the birds.
• One hundred and twenty, one day-old chickens were divided into three groups of 40. All birds in group 1 were vaccinated with coccidia corresponding to those of the ParacoxTM 8 vaccine, in water; the birds in group 2 were vaccinated with the same type of coccidia but in 0.6% w/v Xanthan Gum/0.2% w/v Nacl, and with 0.1% w/v Carmine (E120); both by coarse spray. Birds in group 3 were not vaccinated (see Table 2). All birds were kept in groups in separate floor pens for 21 days post vaccination.
• faecal samples were collected from the floor pens: for the vaccinated birds (groups 1 and 2) daily from day 4 to day 14 and on day 20 post vaccination (pv); for the control birds (group 3) on days 7, 14 and 20.
• each bird was challenged with 15,000 oocysts of a virulent E. tenella wild type strain.
• the challenged birds were transferred to collection cages (3 cages of 10 birds per group) in containment rooms.
• the remaining birds in groups 1 & 2 were euthanized and discarded.
• the remaining birds in group 3 were left in the floor pen to be weighed on days 21, 28 and 35. Two birds were not vaccinated and not challenged, to allow detection of any non-experimental infection.
• Chickens used were SPF, of mixed sex, and one day old at the start of the experiment. All birds were checked for being of apparent good health and size before vaccination. The birds were allocated to the groups in a randomised way, on a first caught basis. Tap water and standard feed were available ad libitum. Challenge inoculation was by oral gavage.
• Vaccine coccidia (as in Paracox 8) and challenge materials (sterile, sporulated oocysts of E. tenella ) were kept at 2-8° C. until use, and were well within their expiry date at the time of the experiment.
• the Paracox 8 vaccine coccidia were diluted to provide one animal dose in 0.21 ml; the vaccine for groups 1 and 2 were made up to contain 3,000 doses.
• the diluents were held in separate sterile glass Duran bottles either 315 ml of sterile water for group 1, or for group 2: 315 ml of (heat sterilised) 1.2 w/v Xanthan Gum (Xantural 11K, CP Kelco) and 0.4% w/v NaCl, both containing 0.2% w/v Carmine. Two, 5000 dose sachets were shaken and massaged vigorously for 1 minute to ensure re-suspension of the oocysts.
• the concentration of the oocysts in the challenge material was determined using a modified Fuchs-Rosenthal counting chamber. From this a dilution was made to provide 15.000 oocysts per animal dose of 0.5 ml.
• a SpraycoxTM II machine was used following the manufacturers instructions, to apply a coarse spray vaccine to the chicken hatchlings. As the machine is designed to vaccinate 100 chicks per tray, for the 40 chicks per groups used here, the tray area was reduced by 60%. A paper tray liner was used to provide a good surface which allowed the birds to move freely and preen themselves and each other.
• the target was to administer 0.21 ml of vaccine per bird, therefore 21 ml of vaccine was applied per tray.
• the Spraycox machine's settings were calibrated by several mock runs to ensure that the correct dose (21 ml) was dispensed over the total internal surface area of the tray before the vaccination of the groups in the experiment.
• the prepared vaccines were shaken for 10 minutes prior to being transferred to the Spraycox machine, to ensure thorough mixing of the vaccine.
• Once vaccinated birds were kept for at least 30 minutes in the trays in which they were vaccinated, in a well-lit and warm area before being transferred to the floor pens. The birds were monitored during this time to see how quickly the vaccine was taken up. Between each vaccination, the spray machine's settings were re-confirmed, and the machine was thoroughly rinsed out with warm water.
• the groups were vaccinated in order i.e. group 1 before 2.
• Post challenge bulked faecal samples were collected from challenged cages between days 4 and 7 post challenge. The sample from each cage was separately collected on plastic sheets to determine the total oocyst output after challenge. Faeces were sprayed with water at least daily to ensure that they were kept moist. Each sample was double bagged, labelled to identify the contents, and stored at 2-8° C. until processing. The oocysts were recovered as per standard practices and the numbers calculated using the McMaster counting technique.
• the amounts of oocysts detected in the faecal collections are summarised in Tables 4 (taken post vaccination) and 5 (post challenge). Post vaccination there is good oocyst output showing that the vaccination was successful. Also the patterns of the oocyst output are as expected: an initial peak in oocyst output, directly resulting from the vaccination, followed by a drop in output, followed by a second peak, six days after the first, as the oocysts go through their second cycle. In group 2 the initial peak in oocyst output, although smaller than that in group 1, is earlier by three days and results in a larger second peak.
• the vaccine delivered in the Xanthan gum formulation provided greater immunity to the birds against challenge at 21 days post vaccination, as compared to the same vaccine but delivered in water. All of the three parameters used to assess vaccination efficacy: lesion scores, increase in bodyweight gain, and reduction of oocyst output, were significantly improved for the group receiving the vaccine in Xanthan gum, as compared to the traditional vaccine in water group and to the unvaccinated control group.
• the vaccine had been prepared using heat-sterilised Xanthan gum, this had been provided with a concentration of metal salt so as to stabilise it during the heating.
• the strongly improved vaccine efficacy is due to an improved ingestion of vaccine, delivered in the Xanthan gum, demonstrated by the earlier output of vaccinal oocysts and improved re-cycling. This lead to an impressive reduction in lesion scores and oocyst output, as well as to an economically highly relevant increase in bodyweight gain post challenge.
• ‘vaccine take’ is determined at 5-7 days post vaccination, at post mortem, by a microscopic examination of scrapings from the intestinal-wall. To detect the various species of Eimeria , different regions of the gut need to be monitored.
• the experimental set-up was highly similar in design and performance to the experiment described in Example 2.
• 75 day-old SPF chickens were randomly allocated to three groups of 25 birds. Each group was vaccinated with E. tenella by coarse spray, administered at a dose level of 0.21 ml, i.e about 500 coccidia per bird, using a commercial Spraycox II machine.
• the vaccine coccidia used were of the E. tenella strain as is present in the Paracox product.
• Post vaccination the birds were left to preen and take up the vaccine; they were then transferred to isolators at 1 group per isolator, and brooded for 7 days. Birds were observed daily. At 7 days p.v. the birds were euthanased and examined post mortem for the presence of oocysts or developing stages in their gut.
• Vaccine uptake was determined by microscopical examination of wet smears from both caecal pouches. Scores were either positive or negative depending on the presence or absence of parasitic stages, see Table 6.
• the uptake of the vaccine is affected by the formulation in which it is applied.
• the use of 0.6% Xanthan gum (group 2) improved the uptake of the vaccine by 30%, namely from 54.5% with the traditional water medium (group 1) to 70.8%.
• the use of 3% PVP (group 3) actually reduced the uptake of vaccine by 20%, when compared with the water group, namely from 54.5 to 43.5%.
• the use of the 0.6% Xanthan gum in the formulation of a spray vaccine of Eimeria oocysts has a clear positive effect on the uptake of oocysts, compared to the use of 3% PVP, or the use of conventional plain water as medium.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Tropical Medicine & Parasitology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=55085492

Family Applications (2)

Family Applications After (1)

Country Status (8)

Cited By (2)

Families Citing this family (1)

Family Cites Families (13)

• 2016
  • 2016-12-23 RU RU2018127638A patent/RU2767913C2/ru not_active Application Discontinuation
  • 2016-12-23 US US16/064,027 patent/US20190000950A1/en not_active Abandoned
  • 2016-12-23 CN CN201680077099.2A patent/CN108472351A/zh active Pending
  • 2016-12-23 JP JP2018533869A patent/JP6955497B2/ja active Active
  • 2016-12-23 MX MX2018008091A patent/MX2018008091A/es unknown
  • 2016-12-23 WO PCT/EP2016/082530 patent/WO2017114775A1/en active Application Filing
  • 2016-12-23 EP EP16825434.0A patent/EP3397278A1/en not_active Withdrawn
  • 2016-12-23 BR BR112018013082A patent/BR112018013082A2/pt unknown
• 2020
  • 2020-06-26 US US16/913,857 patent/US11413343B2/en active Active

Also Published As

Similar Documents

Legal Events